Dr. Pietanza on Rova-T for Small Cell Lung Cancer

Video

Catherine Pietanza, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses novel targeted therapy rovalpituzumab tesirine (Rova-T), which showed activity in relapsed and refractory small cell lung cancer (SCLC) in a recent phase I study.

Catherine Pietanza, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses novel targeted therapy rovalpituzumab tesirine (Rova-T), which showed activity in relapsed and refractory small cell lung cancer (SCLC) in a recent phase I study.

The study looked at patients with SCLC who were positive for delta-like 3 (DLL3). In these DLL3-expressing patients, there was an overall response rate (ORR) of about 45%. The results were particularly significant because these patents do not currently have many therapeutic options, explains Pietanza.

DLL3 is overexpressed at a variety of levels, and highly expressed in over 70% of patients, meaning it is possible that this targeted therapy will work for a large number of those with SCLC. Further trials are planned.

<<<

View more from the 2015 European Cancer Congress

Related Videos
Pat Furlong, BSN, RN
N. Nora Bennani, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
David Porter, MD
Heather Lau, MD, MS, the executive director of global clinical development at Ultragenyx Pharmaceutical
Peter A. Merkel, MD, MPH, the chief of the Division of Rheumatology and a professor of medicine and professor of epidemiology at Penn Medicine
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
Julie Kanter, MD
Salvador Rico, MD, PhD
Marcela Maus, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.